IP Library Granted Patent US 9,132,137
Granted Patent B2
US 9,132,137 · App. 12/947,397 · Granted Sep 15, 2015

Graduated estrogen contraceptive

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,132,137
App. No.
12/947,397
Granted
Sep 15, 2015
Kind
B2
Abstract

A multiphasic estrogenic/progestogenic contraceptive regimen that provides for the reduction or elimination of estrogen in the initial phase is disclosed. Also described is a contraceptive kit that may be used to practice the method of the invention.

Claims (14)

1. A multiphase combination and contraceptive kit comprising a package containing daily dosages of:

(a) a Phase I composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 0.5 to about 5 mcg of ethinyl estradiol;

(b) a Phase II composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 10 to about 50 mcg of ethinyl estradiol; and

(c) a Phase III composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 25 to about 50 mcg of ethinyl estradiol, wherein the amount of estrogen in the Phase III composition is greater than the amount of estrogen in the Phase II composition by at least an amount equivalent to 5 mcg ethinyl estradiol;

wherein the kit contains about 5 to about 9 dosages of the Phase I composition; about 5 to about 9 dosages of the Phase II composition; about 8 to about 12 dosages of the Phase III composition and about 1 to about 4 dosages of a Phase IV composition which contains ferrous fumarate or is a placebo; and the total number of dosages from Phase I, II, III and IV in the kit is 28.

2. The kit according to claim 1 , wherein the progestogen in each Phase is norethindrone acetate.

3. The kit according to claim 2 , wherein the estrogen in each Phase is ethinyl estradiol.

4. The kit according to claim 3 , wherein the Phase II composition contains about 20 to about 40 mcg of ethinyl estradiol and the Phase III composition contains about 25 to about 50 mcg of ethinyl estradiol.

5. The kit according to claim 1 , wherein each of the Phase I, II and III compositions contains a progestogen in an amount equivalent to about 0.5 to about 1.5 mg of norethindrone acetate.

6. The kit according to anyone of claims 2 to 4 , wherein each of the Phase I, II and III compositions contains norethindrone acetate in an amount from about 0.5 to about 1.5 mg.

7. The kit according to claim 4 , wherein the Phase I composition contains about 1 mg of norethindrone acetate, the Phase II composition contains about 1 mg of norethindrone acetate and about 30 mcg of ethinyl estradiol, the Phase III composition contains about 1 mg of norethindrone acetate and about 35 mcg of ethinyl estradiol, and the Phase IV composition contains about 75 mg of ferrous fumarate.

8. The kit according to claim 7 , wherein the kit contains about 7 dosages of the Phase I composition, about 7 dosages of the Phase II composition, about 10 dosages of the Phase III composition and about 4 dosages of the Phase IV composition.

9. The kit according to claim 7 , wherein the Phase I composition contains about 5 mcg of ethinyl estradiol.

10. The kit according to claim 8 , wherein the Phase I composition contains about 5 mcg of ethinyl estradiol.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2021
From: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
To: ALLERGAN THERAPEUTICS LLC
Reel/Frame 057605/0461 →
CORRECTIVE ASSIGNMENT TO CORRECT THE US PATENT NO. 8,050,873 PREVIOUSLY RECORDED ON REEL 040183 FRAME 0129. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 22, 2018
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 045417/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 040183/0129 →